Biogen's big year turning into unprecedented rollercoaster

27 September 2021
aduhelm_biogen_large

Of all the chief executives of the world’s major biopharmaceutical companies, the one who could be excused for spending the most sleepless nights so far in 2021 is Michel Vounatsos.

The Biogen (Nasdaq: BIIB) boss has seen his company go through more highs and lows over the past eight months than many drugmakers do in a decade, with the highlights and lowlights including a milestone US Food and Drug Administration (FDA) approval and congressional committees making claims of an unnaturally close relationship between the firm and the agency.

A storm brewing over years

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology